2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Pulmonary TB: new trials by email Literature Review of Pulmonary TB trials Research Report on Pulmonary TB
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis 10 mg OPC-167832, 30 mg OPC-167832, 90 mg OPC-167832 - Pulmonary TB | Phase 1 / Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 122 | 2018-10-18 | 2023-11-18 |
| Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults ID93 + GLA-SE - Pulmonary TB | Phase 1 | Completed | Access to Advanced Health Institute (AAHI) | 48 | 2018-10-02 | 2023-06-01 |
Actinomycetales Infections (2) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Gram-Positive Bacterial Infections (2) · Infections (2) · Lung Diseases (2) · Mycobacterium Infections (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Tuberculosis (2)
OPC-67683 (1)
Access to Advanced Health Institute (AAHI) (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1)
South Africa (1) · United States (1)
Christopher Fox, PhD (1) · Prof. Andreas Diacon (1) · Prof. Rodney Dawson, MD (1) · Veronique R de Jager, MD (1)
PMID 36878897, PMID 39612928, PMID 41121745
272201400041C-0-0-1 (1)